Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma. 2002

Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

BACKGROUND The long-term prognosis after resection for patients with hepatocellular carcinoma is still unsatisfactory because of the high recurrence rate. The survival of patients with multiple intrahepatic or extrahepatic recurrence is especially poor. METHODS Among the patients who underwent hepatic resection for hepatocellular carcinoma between 1981 and 2000, 216 patients with 3 or less than 3 intrahepatic recurrences (group B); 156 patients with more than 3 intrahepatic recurrences, extrahepatic recurrences, or both (group C); and 51 patients who survived more than 5 years without recurrence (group A) were clinicopathologically studied. RESULTS The period to recurrence of group C was significantly earlier than that of group B and also showed a significantly poor prognosis after recurrence. Tumor factors, including size, portal venous invasion, intrahepatic metastasis, histologic grade, or the number of tumors at resection in group C was significantly worse than in groups A and B. Although no differences are recognized in the tumor factors between groups A and B, except for the alpha-fetoprotein level, liver function in group B was significantly worse than that in group A. In addition, the frequency of hepatitis B surface antigen in group B and that of hepatitis C virus in group B was significantly less and higher than that in group A, respectively. CONCLUSIONS Similar to extrahepatic metastasis, multinodular recurrences are also mainly caused by metastatic recurrence from the main tumor by means of the portal system, and recurrences with up to 3 intrahepatic nodules are mainly caused by metachronous multicentric hepatocarcinogenesis. Because the mechanisms of recurrence differed, determining the patterns of recurrence on the basis of the clinicopathologic findings is important for selecting the optimal postoperative therapy for each individual patient.

UI MeSH Term Description Entries
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D005260 Female Females
D006498 Hepatectomy Excision of all or part of the liver. (Dorland, 28th ed) Hepatectomies
D006526 Hepatitis C INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted,Parenterally-Transmitted Non-A, Non-B Hepatitis,PT-NANBH,Parenterally Transmitted Non A, Non B Hepatitis
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000410 Alanine Transaminase An enzyme that catalyzes the conversion of L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. (From Enzyme Nomenclature, 1992) EC 2.6.1.2. Alanine Aminotransferase,Glutamic-Pyruvic Transaminase,SGPT,Alanine-2-Oxoglutarate Aminotransferase,Glutamic-Alanine Transaminase,Alanine 2 Oxoglutarate Aminotransferase,Aminotransferase, Alanine,Aminotransferase, Alanine-2-Oxoglutarate,Glutamic Alanine Transaminase,Glutamic Pyruvic Transaminase,Transaminase, Alanine,Transaminase, Glutamic-Alanine,Transaminase, Glutamic-Pyruvic

Related Publications

Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
February 2010, Hepatobiliary & pancreatic diseases international : HBPD INT,
Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
August 2012, Korean journal of hepato-biliary-pancreatic surgery,
Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
January 2005, Hepato-gastroenterology,
Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
October 2014, Hepato-gastroenterology,
Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
January 1993, Cancer,
Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
October 2016, World journal of surgery,
Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
January 2012, World journal of surgery,
Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
April 2011, The American journal of the medical sciences,
Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
January 2022, World journal of surgery,
Eisuke Adachi, and Shin-ichiro Maehara, and Eiji Tsujita, and Ken-ichi Taguchi, and Shin-ichi Aishima, and Tatsuya Rikimaru, and Yo-ichi Yamashita, and Shinji Tanaka
January 2006, World journal of gastroenterology,
Copied contents to your clipboard!